From Nasdaq MarketSite: 2025-04-30 20:42:00

Satsuma Pharmaceuticals Inc. receives FDA approval for Atzumi nasal powder for treating migraines in adults, previously known as STS101. Atzumi is not for prevention or managing specific types of migraines. Migraine affects approximately 40 million Americans, ranking as the second leading cause of disability globally and the most common among young women. Symptoms are debilitating, stemming from temporary changes in the brain’s chemicals, nerves, and blood vessels. For more health news, visit rttnews.com.



Read more at Nasdaq MarketSite: FDA Approves Satsuma Pharma’s Atzumi Nasal Powder For Acute Treatment Of Migraine